Conv. Plasma
Nigella Sativa
Peg.. Lambda

All aspirin studies
Meta analysis
Home COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 4% Improvement Relative Risk Aspirin for COVID-19  Yuan et al.  Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? Retrospective 183 patients in China Study underpowered to detect differences Yuan et al., J. Cellular and Molecular.., Dec 2020 Favors aspirin Favors control

Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease

Yuan et al., Journal of Cellular and Molecular Medicine, doi:10.1111/jcmm.16198
Dec 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 183 hospitalized patients in China, 52 taking low-dose aspirin prior to hospitalization, showing no significant difference with treatment.
risk of death, 4.4% lower, RR 0.96, p = 0.89, treatment 11 of 52 (21.2%), control 29 of 131 (22.1%), NNT 102, odds ratio converted to relative risk, mutivariate.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yuan et al., 18 Dec 2020, retrospective, China, peer-reviewed, 6 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Mortality and pre‐hospitalization use of low‐dose aspirin in COVID‐19 patients with coronary artery disease
Shuai Yuan, Peng Chen, Huaping Li, Chen Chen, Feng Wang, Dao Wen Wang
Journal of Cellular and Molecular Medicine, doi:10.1111/jcmm.16198
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section. How to cite this article:
Ajani, Ford, Greenland, Giles, Mokdad, Aspirin use among U.S. adults: behavioral risk factor surveillance system, Am J Prev Med
Alamdari, Afaghi, Rahimi, Mortality risk factors among hospitalized COVID-19 patients in a major referral center in Iran, Tohoku J Exp Med
Asghar, Aghazadeh-Habashi, Jamali, Cardiovascular effect of inflammation and nonsteroidal anti-inflammatory drugs on renin-angiotensin system in experimental arthritis, Inflammopharmacology
Cardiology, <COVID-19 clinical guidance for the cardiovascular care team>
Chow, Khanna, Kethireddy, Aspirin use is associated with decreased mechanical ventilation, ICU admission, and in-hospital mortality in hospitalized patients with COVID-19, Anesth Analg
Clerkin, Fried, Raikhelkar, Coronavirus disease 2019 (COVID-19) and cardiovascular disease, Circulation
Day, Covid-19: European drugs agency to review safety of ibuprofen, BMJ
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect Dis
Duffy, Kelly, Whellan, Mills, Aspirin for cardioprotection and strategies to improve patient adherence, Postgrad Med
Fitzgerald, Misguided drug advice for COVID-19, Science
Gorbalenya, Baker, Baric, The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, Nat Microbiol
Gorelick, Weisman, Risk of hemorrhagic stroke with aspirin use: an update, Stroke
Gu, Dillon, Eberhardt, Wright, Burt, Preventive aspirin and other antiplatelet medication use among U.S. Adults aged ≥ 40 years: data from the national health and nutrition examination survey, 2011-2012, Public Health Rep
Guan, Ni, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med
Hennekens, Dyken, Fuster, Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association, Circulation
Ittaman, Vanwormer, Rezkalla, The role of aspirin in the prevention of cardiovascular disease, Clin Med Res
Kwiatkowski, Borowski, Kajdy, Poon, Rokita et al., Why we should not stop giving aspirin to pregnant women during the COVID-19 pandemic, Ultrasound Obstet Gynecol
Levi, Thachil, Iba, Levy, Coagulation abnormalities and thrombosis in patients with COVID-19, Lancet Haematol
Lippi, Plebani, Henry, Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis, Clin Chim Acta
Mathilde, Rolnik, Hoffman, Panchaud, Baud, Should we stop aspirin prophylaxis in pregnant women diagnosed with COVID-19?, Ultrasound Obstet Gynecol
Russell, Moss, Rigg, Van Hemelrijck, COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancermedicalscience
Tang, Bai, Chen, Gong, Li et al., Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J Thromb Haemost
Voiriot, Philippot, Elabbadi, Elbim, Chalumeau et al., Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients, J Clin Med
Wang, Hu, Hu, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in
Wichmann, Sperhake, Lütgehetmann, Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study, Ann Intern Med
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention, JAMA
Yang, Ng, Li, Thrombocytopenia in patients with severe acute respiratory syndrome (review), Hematology
Zheng, Ma, Zhang, Xie, COVID-19 and the cardiovascular system, Nat Rev Cardiol
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, The Lancet
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop